You are here: Industry Insights > Novartis

News List

Novartis Provides Additional Phase III Data for MS Drug Siponimod: Prepares to Seek FDA Approval biospace
April 23, 2018
Novartis released new information that showed the drug consistently reduced the risk of confirmed disability progression in secondary progressive multiple sclerosis (SPMS) patients.
Novartis snatches Amgen and BMS veteran for CMO and Drug Development Head pharmafile
April 20, 2018
Dr John Tsai has been welcomed to the fold as Novartis’ new Head of Global Development and Chief Medical Officer, stepping into the role vacated by Dr Vas Narasimhan, who has since taken up the mantle of CEO at the company.
Novartis Sees Sharp Decline in Generic Drug Sales During First Quarter biospace
April 20, 2018
Shares of Novartis are down nearly 3 percent this morning after the company reported a sharp decline in generic drugs and sales results from key branded medicines that missed analysts’ projections for the first quarter.
Amgen Exec John Tsai to Head Novartis’ Global Drug Development biospace
April 20, 2018
Novartis announced that John Tsai, formerly of Amgen, is joining the company as Head of Global Drug Development and chief medical officer.
Novartis to Spend $100M on Malaria Initiative biospace
April 18, 2018
One of the nastier viruses carried by mosquitoes, malaria, was responsible for the deaths of more than 445,000 people in 2016.
Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes firstwordpharma
April 17, 2018
Novartis today announced a new post hoc analysis of the pivotal Phase III heart failure study
Novartis' Entresto helps preserve kidney function in chronic heart failure patients pharmafile
April 17, 2018
Novartis has raised curtains from the 3 phase of clinical trials to protect the kidney function of patients with reduced ejection fraction of heart failure Entresto data.
Novartis’ Afinitor Disperz wins new TSC-related approval pharmatimes
April 12, 2018
Novartis’ Afinitor Disperz has become the first medicine to be specifically approved by US regulators to treat patients aged two years and above with tuberous sclerosis complex (TSC)-associated partial-onset seizures.
Does Novartis’s Acquisition of AveXis Spell Trouble for Biogen? biospace
April 11, 2018
Switzerland-based Novartis is buying Bannockburn, Illinois-based AveXis for $8.7 billion. This could spell big trouble for Cambridge, Massachusetts-based Biogen.
Novartis to buy AveXis for $8.7B biospectrumasia
April 10, 2018
Novartis expects the acquisition to "strongly contribute" to core operating income and earnings per share.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page